Figure 4From: Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritisChanges in serum biomarkers between baseline (week 0) and week 4 of etanercept treatment (n = 20) in peripheral spondyloarthritis (SpA). Paired t-tests were performed. Data are represented as mean (standard error of the mean). *P <0.05. hs-CRP, high-sensitivitivity C-reactive protein; MMP-3, matrix metalloproteinase-3.Back to article page